Pre-clinical Microbiology — Gram-positive Cocci

Autor: Silvano Esposito
Rok vydání: 2000
Předmět:
Zdroj: First International Moxifloxacin Symposium ISBN: 9783642640810
Popis: Despite increased funding of health care and medical research in the field of bacterial infections, the secular trend of morbidity and mortality caused by bacterial infections has likely increased due to emerging pathogens and to bacterial resistance. Gram-positive cocci play an important role in the aetiology of bacterial infections in both hospital and community settings. A special CDC Committee (Atlanta, GA, USA) recently identified five major priorities to fight antibiotic resistance:Enterococcusspp.,Staphylococcusspp.,Mycobacterium tuberculosis, Streptococcus pneumoniaeandNeisseria gonorrhoeae. Three priorities concern Gram-positive cocci, therefore agents active against these organisms are welcome. Moxifloxacin has greater antibacterial activity againstE. faecalisandE. faeciumthan ampicillin and ciprofloxacin. It is also active against some strains of vancomycin-resistant enterococci, against MSSA and, in contrast to previous generations of fluoroquinolones, against MRSA. These data suggest that moxifloxacin represents an attractive option for difficult-to-treat infections. AlthoughStreptococcus pyogenes is not a priority identified by the CDC, it is of concern due to the development of resistance to macrolides. Moxifloxacin has excellent antibacterial activity against GABHS, which is not affected by macrolide resistance. Its use may be indicated for treatment ofS. pyogenes-related diseases in adults with a history of allergy to beta-lactams.
Databáze: OpenAIRE